{"analyses":[{"ciLowerLimit":"0.99","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.48","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"1.21","statisticalMethod":"Poisson regression"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7"},{"groupId":"OG001","value":"5.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34304"},{"groupId":"OG001","value":"34253"}],"units":"Participants"}],"description":"Ovarian cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as ovarian cancer diagnoses divided by person years at risk for ovarian cancer.","groups":[{"description":"Participants receive standard medical care.","id":"OG000","title":"Control"},{"description":"Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years.","id":"OG001","title":"Ovarian Screening"}],"paramType":"NUMBER","populationDescription":"Female participants, excluding females without ovaries at baseline, were analyzed. An intention-to-treat analysis was performed.","reportingStatus":"POSTED","timeFrame":"Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.","title":"Ovarian Cancer Incidence Rates (Including Primary Peritoneal and Fallopian Tube Cancers).","type":"SECONDARY","unitOfMeasure":"Diagnoses per 10,000 PY"}